RESEARCH ARTICLE

Exercise gas exchange in continuous-flow left ventricular assist device recipients

Alessandro Mezzani1*, Massimo Pistono1, Piergiuseppe Agostoni2, Andrea Giordano3, Marco Gnemmi1, Alessandro Imparato4, Pierluigi Temporelli4, Ugo Corrà1

1 Exercise Pathophysiology Laboratory, Cardiac Rehabilitation Division, Scientific Institute of Veruno IRCCS, Istituti Clinici Scientifici Maugeri Spa SB, Veruno (NO), Italy, 2 Centro Cardiologico Monzino IRCCS and Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy, 3 Bioengineering Service, Scientific Institute of Veruno IRCCS, Istituti Clinici Scientifici Maugeri Spa SB, Veruno (NO), Italy, 4 Echocardiography Laboratory, Cardiac Rehabilitation Division, Scientific Institute of Veruno IRCCS, Istituti Clinici Scientifici Maugeri Spa SB, Veruno (NO), Italy

* a.mezzani@orpea.net

Abstract

Exercise ventilation/perfusion matching in continuous-flow left ventricular assist device (LVAD) recipients has not been studied systematically. Twenty-five LVAD and two groups of 15 reduced ejection fraction chronic heart failure (HFrEF) patients with peak VO2 matched to that of LVAD (HFrEF-matched) and ≥14 ml/kg/min (HFrEF≥14), respectively, underwent cardiopulmonary exercise testing with arterial blood gas analysis, echocardiogram and venous blood sampling for renal function evaluation. Arterial-end-tidal PCO2 difference (P(a-ET)CO2) and physiological dead space-tidal volume ratio (VD/VT) were used as descriptors of alveolar and total wasted ventilation, respectively. Tricuspid annular plane systolic excursion/pulmonary artery systolic pressure ratio (TAPSE/PASP) and blood urea nitrogen/creatinine ratio were calculated in all patients and used as surrogates of right ventriculo-arterial coupling and circulating effective volume, respectively. LVAD and HFrEF-matched showed no rest-to-peak change of P(a-ET)CO2 (4.5±2.4 vs. 4.3±2.2 mm Hg and 4.1±1.4 vs. 3.8±2.5 mm Hg, respectively, both p >0.40), whereas a decrease was observed in HFrEF≥14 (6.5±3.6 vs. 2.8±2.0 mm Hg, p <0.0001). Rest-to-peak changes of P(a-ET)CO2 correlated to those of VD/VT (r = 0.70, p <0.0001). Multiple regression indicated TAPSE/PASP and blood urea nitrogen/creatinine ratio as independent predictors of peak P(a-ET)CO2. LVAD exercise gas exchange is characterized by alveolar wasted ventilation, i.e. hypoperfusion of ventilated alveoli, similar to that of advanced HFrEF patients and related to surrogates of right ventriculo-arterial coupling and circulating effective volume.

Introduction

Continuous-flow left ventricular assist devices (LVAD) are increasingly used as destination therapy in end-stage reduced ejection fraction chronic heart failure (HFrEF) patients [1–3]. However, most studies show that last generation devices have modest effects on functional capacity [4–8]. This is due to both the severe functional impairment of patients prior to LVAD
implantation and the scarce ability of the fixed-speed LVAD/dysfunctioning native left ventricle combination to cope with increasing preload during exercise [9,10]. As a consequence, not only have training programs of LVAD recipients been implemented [11], but also devices able to adapt pump-generated blood flow to exercise energetic demands have been conceived [12,13]. Quite surprisingly, however, gas exchange dynamics and ventilation/perfusion matching during exercise [14–16] have not been systematically evaluated as yet in LVAD recipients.

The aim of this study was to compare respiratory and arterial blood exercise gas exchange of a group of LVAD-implanted patients with those of two groups of HFrEF patients with similarly reduced and significantly higher peak volume of oxygen uptake (peak VO\textsubscript{2}), respectively. Due to the inability of LVAD to significantly increase systemic blood flow in response to exercise [8–10,17,18], we hypothesized that LVAD recipients would show exercise gas exchange characterized by a high ventilation/perfusion ratio due to wasted ventilation of underperfused alveoli.

**Materials and methods**

**Study population**

Fifty-two consecutive LVAD recipients referred to our Institute for assessment of clinical status and rehabilitation were evaluated. Indication for LVAD implantation was hemodynamic decompensation due to ischemic or idiopathic HFrEF not responsive to intensive medical therapy. Inclusion criteria were: 1) clinical stability for 30 days prior to evaluation; 2) ability to carry out a cardiopulmonary exercise test; 3) possibility to take an arterial blood sample at rest and peak exercise; 4) respiratory exchange ratio ≤0.90 during arterial blood sampling at rest.

Accordingly, 25 patients were enrolled. Exclusion of the remaining 27 patients was due to: lack of clinical stability and/or inability to carry out a cardiopulmonary exercise test (n. = 15, 29%), arterial blood sampling at rest and/or peak exercise not feasible (n. = 7, 13%) and resting respiratory exchange ratio >0.90 (n. = 5, 10%). Two groups of HFrEF patients with peak VO\textsubscript{2} matched to that of LVAD or ≥14 ml/kg/min (HFrEF-matched and HFrEF≥14, respectively) were used as controls. Inclusion criteria for HFrEF were the same as those used for LVAD, with the addition of history of HFrEF from ischemic or idiopathic dilated cardiomyopathy and clinical/pharmacological stability for at least three months at the time of evaluation.

The protocol was approved by the Central Ethics Committee of the Salvatore Maugeri Foundation, IRCCS and informed written consent was obtained from all participants. The work has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

**Cardiopulmonary exercise test**

Cardiopulmonary exercise test was carried out on an electromagnetic bicycle ergometer (Ergo-metrics 800S, Sensormedics, Yorba Linda, CA, USA), using a ramp incremental (5, 7 or 10 W/min) protocol at a pedaling rate of 60 revs/min. Respiratory gas exchange measurements were obtained breath-by-breath (Vmax29, Sensormedics) using a mouthpiece as patient/metabolic cart interface. Peak VO\textsubscript{2} was the highest 30 s average VO\textsubscript{2} value over the last minute of the exercise phase. The first ventilatory threshold (1\textsuperscript{st}VT) was estimated by the V-slope and/or as the nadir of the VE vs. VO\textsubscript{2} relationship and the second ventilatory threshold (2\textsuperscript{nd}VT), when present, as the nadir of the VE vs. VCO\textsubscript{2} relationship (16).

The slope of the ventilation vs. volume of exhaled carbon dioxide (VCO\textsubscript{2}) relationship (VE/VCO\textsubscript{2} slope) was evaluated excluding, when present, its final nonlinear portion due to acidicotic ventilatory drive. Blood pressure was measured at rest and every two minutes during the exercise and recovery phases; a manual cuff sphygmomanometer was used in HFrEF.
patients, whereas and automated electronic device (Dinamap, GE Healthcare, Waukesha, WI, USA) was used in LVAD recipients.

**Arterial blood gas analysis**

Arterial blood was sampled at rest and during the last minute of exercise from a radial artery, and immediately analyzed for blood gases and hemoglobin content (GEM® Premier 4000, Instrumentation Laboratory, Lexington, MA, USA). Operators took note of the time elapsed from the start of the rest and exercise phases and arterial blood sampling, which allowed temporal alignment of arterial blood and ergospirometric data.

**Venous blood analysis**

Fasting blood samples were drawn from an antecubital vein within 3±2 days prior to cardiopulmonary exercise testing. Blood samples (4 ml) were collected in EDTA vacutainers, and centrifuged at 3000 rpm at room temperature for 10 min. Plasma fractions (2–3 ml) were collected in appropriately labeled, sterile cryotubes, stored at -80˚C and subsequently analyzed for blood urea nitrogen (BUN) by kinetic UV assay (Cobas® e 601, Roche Diagnostics US, Indianapolis, IN, USA), creatinine by Jeffé method (Cobas® e 601, Roche Diagnostics US) and N-terminal pro-brain natriuretic peptide (NT pro-BNP) by enzyme linked fluorescent assay (miniVIDAS®, bioMérieux SA, Marcy l’Etoile, FR). The BUN/creatinine ratio was calculated and used as a surrogate of circulating effective volume (Rose, 2000).

**Gas exchange**

Ventilation/perfusion mismatch characterized by a high ventilation/perfusion ratio, i.e. by hypoperfusion of normally ventilated alveoli, determines an increase of physiological dead space (VD) and wasted ventilation. Arterial-end-tidal PCO$_2$ difference ($P(a-ET)CO_2$, mmHg) was used as a descriptor of alveolar wasted ventilation, and physiological dead space-tidal volume ratio ($VD/VT$) as an index of total wasted ventilation [14,16,19]. $VD/VT$ was calculated as (16)

$$VD/VT = \frac{\left(\frac{PaCO_2 - PECO_2}{PaCO_2}\right) - VD_m}{VT - VD_m}$$

where VT (l) is tidal volume, $PaCO_2$ is arterial PCO$_2$ (mm Hg, assumed to be equal to ideal alveolar PCO$_2$), $PECO_2$ (mm Hg) is mixed expired PCO$_2$, equal to $[VCO_2 (l/min, STPD) / \text{ventilation (l/min, STPD)}] \times (PB - 47)$, and $VD_m$ (l) is breathing valve dead space (0.075 l).

Ventilation/perfusion mismatch characterized by a low ventilation/perfusion ratio, i.e. by hypoventilation of normally perfused alveoli and/or of diffusion limitation to gas exchange, is described by an increased alveolar-arterial PO$_2$ difference ($P(A-a)O_2$, mm Hg) [14,16,19]. Alveolar PO$_2$ ($PAO_2$, mm Hg) was calculated as (16)

$$PAO_2 = \left[FIO_2 \times (PB - 47)\right] - PaCO_2 / RER$$

where $FIO_2$ is the fraction of inspired O$_2$, dry, PB (mm Hg) is barometric pressure and RER is respiratory exchange ratio.

**Spirometry and lung diffusing capacity**

Forced vital capacity and forced expiratory volume in 1 s were measured through a mass flow sensor (Vmax22, Sensormedics) according to the American Thoracic Society/European Respiratory Society criteria [20], and expressed as percentage of predicted values [21]. Lung diffusing capacity for carbon monoxide (DL$_{CO}$) was measured using the single breath-hold
maneuver following the recommendations of the American Thoracic Society [22] corrected for hemoglobin values [23] and reported as percentage of predicted values [24]. DL\textsubscript{CO} was also expressed normalized for alveolar volume (DL\textsubscript{CO}/VA) [25].

**Echocardiography**

Echocardiographic imaging (Vivid 7, General Electric Medical Systems, Milwaukee, WI, USA) was performed according to indications for LVAD recipients [26]. Special care was taken to measure tricuspid annular plane systolic excursion (TAPSE) and estimate pulmonary artery systolic pressure (PASP). The TAPSE/PASP ratio (mm/mmHg) was used as a surrogate of the \textit{in vivo} right ventriculo-arterial coupling [27,28].

**Statistics**

One-way analysis of variance with Fisher’s protected least significant difference post hoc tests, repeated-measure analysis of variance with post hoc contrasts and Fisher’s exact test were used to compare quantitative and qualitative variables, as appropriate. The association between continuous variables was explored by simple regression and Pearson product moment coefficients. Multiple regression was used to identify the independent predictors of peak P(a-ET)CO\textsubscript{2} among a set of possible clinical/instrumental determinants of alveolar wasted ventilation. The level of statistical significance was a two-tailed p value of \leq 0.05. The StatView 5.0.1. (SAS Institute, Inc.; Cary, NC, USA) software package was used for statistical calculations.

**Results**

**Demographic and clinical-instrumental characteristics**

Study population demographic and clinical/instrumental characteristics are shown in Table 1. All patients were male. Study groups were well matched as to age and body mass index, with a predominance of ischemic origin of HFrEF and a markedly reduced left ventricular ejection fraction (LVEF). TAPSE and PASP were measurable in all patients. A stepwise significant increase of TAPSE from LVAD to HFrEF$\geq$14 was observed, whereas PASP did not differ between the three groups; accordingly, TAPSE/PASP ratio progressively and significantly increased from LVAD to HFrEF$\geq$14. Forced vital capacity, DL\textsubscript{CO} and DL\textsubscript{CO}/VA did not differ between LVAD, HFrEF-matched and HFrEF$\geq$14.

Analogously, BUN and creatinine were similar in the three study groups; of note, however, BUN/creatinine ratio was significantly lower in LVAD than in HFrEF-matched and HFrEF$\geq$14. NT pro-BNP showed a progressive but non-significant decrease from LVAD to HFrEF$\geq$14. BUN/creatinine ratio was not related with NT pro-BNP either in LVAD or in the whole study population ($r = 0.04$, $p = 0.87$ and $r = 0.23$, $p = 0.31$, respectively). All patients were similarly treated with beta-blockers, whereas a trend towards a higher dosage of loop diuretics in HFrEF-matched than in LVAD and HFrEF$\geq$14 was detected.

**LVAD characteristics**

Table 2 summarizes implanted device characteristics.

Slightly more than half of the patients were implanted with a HeartMate II, and destination therapy or bridge to decision was the indication to implantation in the majority of cases. Time from implantation averaged around seven months. Of note, even though pump speed was higher in HeartMate II than in HeartWare, both resting and peak pump blood flow, as measured by the device controller, were found to be similar in the two groups.
**Table 1. Study population demographic and clinical/instrumental characteristics.**

|                                | LVAD          | HFrEF-matched | HFrEF≥14 | ANOVA and \( \chi^2 \) p |
|--------------------------------|---------------|---------------|----------|--------------------------|
| **n.**                         | 25            | 15            | 15       | /                        |
| **Age (yrs)**                  | 61±5          | 63±9          | 62±6     | 0.60                     |
| **BMI (kg/m\(^2\))**           | 25.65±3.8     | 28.50±4.46    | 26.54±2.5| 0.13                     |
| **Etiology, ischemic [n. (%)]**| 17 (69)       | 11 (73)       | 15 (100) | 0.69                     |
| **LVEF (%)**                   | 27±8          | 30±6          | 32±5     | 0.059                    |
| **TAPSE (mm)**                 | 13±2 **       | 18±4 *        | 21±5     | <0.0001                  |
| **PASP (mmHg)**                | 37±12         | 38±8          | 34±8     | 0.67                     |
| **TAPSE/PASP (mm/mmHg)**       | 0.35±0.12 **  | 0.47±0.15 *   | 0.61±0.17| 0.0049                   |
| **FVC %predicted**             | 74±16 *       | 77±14 *       | 102±15   | <0.0001                  |
| **DL\(_{CO}\) %predicted**    | 65±16         | 75±19         | 72±14    | 0.12                     |
| **DL\(_{CO}\)/VA %predicted** | 71±19         | 72±18         | 65±16    | 0.49                     |
| **Hb (g/dl)**                  | 12.0±1.4 **   | 13.9±1.6      | 15.1±2.3 | <0.0001                  |
| **BUN (mg/dl)**                | 44.0±24.0     | 61.3±28.7     | 46.9±20.3| 0.12                     |
| **Creatinine (mg/dl)**         | 1.25±0.49     | 1.30±0.44     | 1.32±0.95| 0.95                     |
| **BUN/Creatinine**             | 34.5±10.6 **  | 47.1±12.8     | 40.7±15.5| 0.026                    |
| **NT pro-BNP (pg/ml)**         | 2341±1869     | 1880±1571     | 1137±1004| 0.11                     |
| **β-blockers, yes [n. (%)]**   | 20 (80)       | 15 (100)      | 14 (87)  | 0.54                     |
| **Furosemide dosage (mg/day)** | 60±64         | 104±87        | 43±60    | 0.09                     |

LVAD = left ventricular assist device patients; HFrEF-matched = chronic heart failure patients with peak VO\(_2\) matched to that of LVAD; HFrEF≥14 = chronic heart failure patients with peak VO\(_2\) ≥14 ml/kg/min; ANOVA = analysis of variance; BMI = body mass index; LVEF = left ventricular ejection fraction; TAPSE = tricuspid annular plane systolic excursion; PASP = pulmonary artery systolic pressure; FVC %pred. = forced vital capacity as percentage of predicted; DL\(_{CO}\) %pred. = hemoglobin-adjusted lung diffusion capacity for carbon monoxide as percentage of predicted; DL\(_{CO}\)/VA = hemoglobin-adjusted lung diffusion capacity for carbon monoxide normalized for alveolar volume as percentage of predicted; Hb = hemoglobin; BUN = blood urea nitrogen; NT pro-BNP = N-terminal pro-brain natriuretic peptide.

\* = \( p < 0.01 \) vs. HFrEF≥14

\*\* = \( p < 0.01 \) vs. HFrEF-matched and HFrEF≥14.

https://doi.org/10.1371/journal.pone.0187112.t001

**Table 2. Left ventricular assist device characteristics.**

|                                | 25            |
|--------------------------------|---------------|
| **LVAD type [n. (%)]**         | HM 15 (60)    |
|                                | HW 10 (40)    |
| **Indication [n. (%)]**        | BT 3 (12)     |
|                                | BD 5 (20)     |
|                                | DT 17 (68)    |
| **Time since implantation (days)** | 203±115 |
| **Pump speed (rpm)**           | HM 9242±450   |
|                                | HW 2511±97    |
| **Resting PBF (l/min)**        | HM 4.6±0.8    |
|                                | HW 4.1±0.7    |
| **Peak PBF (l/min)**           | HM 6.0±0.9    |
|                                | HW 5.8±1.0    |

HM = HeartMate II; HW = HeartWare; BT = bridge to transplantation; BD = bridge to decision; DT = destination therapy; PBF = pump blood flow.

https://doi.org/10.1371/journal.pone.0187112.t002
Table 3. Cardiopulmonary exercise testing parameters.

| Parameter          | LVAD        | HFrEF-matched | HFrEF≥14     | ANOVA |
|--------------------|-------------|---------------|--------------|-------|
| Resting VO₂ (l/min)| 0.225±0.059 | 0.232±0.60    | 0.254±0.068  | 0.33  |
| Peak VO₂ (l/min)   | 0.827±0.254 | 0.864±0.312   | 1.317±0.290 *| <0.0001|
| Peak VO₂ (ml/kg/min)| 10.6±1.7   | 10.8±1.3      | 17.8±2.8     | <0.0001|
| Peak VO₂% predicted| 39±5       | 41±6          | 66±9 *       | <0.0001|
| Resting VCO₂ (l/min)| 0.192±0.053| 0.194±0.048   | 0.214±0.064  | 0.38  |
| Peak VCO₂ (l/min)  | 0.943±0.3437| 0.985±0.366   | 1.501±0.308 *| <0.0001|
| Resting VE (l/min) | 10.3±2.6   | 10.5±2.0      | 10.8±1.8     | 0.99  |
| Peak VE (l/min)    | 42.1±7.7   | 44.2±4.4      | 53.4±11.4 *  | 0.024 |
| Resting Ve (l)     | 0.567±0.120| 0.548±0.131   | 0.608±0.136  | 0.41  |
| Peak Ve (l)        | 1.423±0.281| 1.420±0.287   | 1.847±0.383 *| 0.0004|
| Resting RR (breaths/min) | 18±5      | 19±3         | 18±5         | 0.63  |
| Peak RR (breaths/min) | 30±4      | 32±8         | 29±5         | 0.29  |
| 1VT, yes [n. (%)]  | 19 (75)    | 12 (80)       | 15 (100)     | 0.19  |
| 2VT, yes [n. (%)]  | 15 (60)    | 11 (73)       | 12 (80)      | 0.27  |
| Resting RER        | 0.83±0.04  | 0.81±0.04     | 0.83±0.05    | 0.40  |
| Peak RER           | 1.14±0.08  | 1.13±0.07     | 1.14±0.06    | 0.90  |
| Resting PETCO (mmHg)| 31.1±4.3   | 31.4±3.6      | 33.3±3.3     | 0.11  |
| Peak PETCO₂ (mmHg) | 27.8±3.7   | 29.4±3.9      | 33.1±4.9 *   | 0.0003|
| Resting HR (beats/min) | 75±12     | 68±12        | 68±12        | 0.18  |
| Peak HR (beats/min) | 107±17     | 106±16       | 122±18 *     | 0.016 |
| Resting O₂ pulse (ml/beat) | 3.0±0.9  | 3.4±1.1      | 3.6±1.4      | 0.24  |
| Peak O₂ pulse (ml/beat) | 7.8±1.6 **| 9.3±2.0      | 10.7±2.4     | 0.0002|
| Resting SBP (mmHg) | 89±8 **    | 110±9        | 122±12       | 0.33  |
| Peak SBP (mmHg)    | /          | 141±13       | 157±10       | 0.39  |
| Peak work rate (W) | 62±14      | 75±22        | 108±24 *     | <0.0001|
| VE/VCO₂ slope      | 40.7±5.2   | 37.8±4.4     | 30.0±3.3 *   | <0.0001|
| EOV [n. (%)]       | 6 (25)     | 4 (27)        | 2 (13)       | 0.11  |

LVAD = left ventricular assist device patients; HFrEF-matched = chronic heart failure patients with peak VO₂ matched to that of LVAD; HFrEF≥14 = chronic heart failure patients with peak VO₂ ≥14 ml/kg/min; ANOVA = analysis of variance; VE = ventilation; Vt = tidal volume; RR = respiratory rate; RER = respiratory exchange ratio; HR = heart rate; SBP = systolic blood pressure; 1VT = first ventilatory threshold; 2VT = second ventilatory threshold; EOV = exercise oscillatory ventilation. * = p < 0.01 vs. LVAD and HFrEF-matched

Cardiopulmonary exercise testing

Cardiopulmonary exercise testing data are shown in Table 3. Resting parameters did not differ between the three study groups, with the only exception of resting systolic blood pressure that was significantly lower in LVAD than in the other two groups. By design, peak VO₂ was lower in LVAD and HFrEF-matched than in HFrEF≥14, and the same was true for peak VCO₂, peak ventilation, peak tidal volume, peak PETCO₂, peak heart rate, peak work rate and VE/VCO₂ slope. Conversely, peak respiratory rate did not differ between the three study groups, so differences in peak ventilation were mostly due to differences in peak tidal volume. No differences in 1VT and 2VT detection were observed in the three study groups, so excluding possible influences of exercise-induced hyperventilation on exercise gas exchange. Peak respiratory exchange ratio was similar in the three groups and on average higher than 1.10, attesting maximal effort attainment in the whole study population. Peak O₂ pulse was significantly lower in LVAD than in the other two groups, consistent with the acknowledged scarce
contribution of the fixed-speed LVAD/dysfunctioning native left ventricle combination to systemic perfusion increase during exercise. Peak systolic blood pressure was not measurable in most LVAD due to technical problems, and did not differ between HFrEF-matched and HFrEF. No differences were observed between the three study groups in the prevalence of exertional oscillatory ventilation, which, when detected, always disappeared in the second half of the exercise phase.

Peak VO$_2$ and VE/VCO$_2$ slope were directly related to TAPSE/PASP (r = 0.56 and 0.49, respectively, both p < 0.001) and LVEF (r = 0.32 and 0.45, respectively, both p < 0.05). In LVAD, neither peak VO$_2$ nor VE/VCO$_2$ slope were related to time elapsed since implantation (r = 0.25 and 0.31, respectively, both p > 0.25).

Arterial blood gas analysis and ventilation/perfusion matching

Arterial blood gas analysis data are shown in Table 4. Resting and peak PO$_2$ and resting and peak hemoglobin O$_2$ saturation did not differ between the three study groups. Significantly higher resting and peak PCO$_2$ values and lower peak pH values were detected in HFrEF$\geq$14 than in LVAD and HFrEF-matched. Overall, the resting picture was consistent with normal arterial blood gas analysis with a slight trend towards respiratory alkalosis in LVAD and HFrEF-matched, whereas at peak exercise compensated (LVAD and HFrEF-matched) and partially compensated metabolic acidosis was evident (HFrEF$\geq$14).

P(a-ET)CO$_2$ at rest was normal in LVAD and HFrEF-matched and higher than normal in HFrEF$\geq$14, and at peak exercise positive values were found in all groups (Table 5). Of note, a significant time [rest/peak exercise] × main effect [study group] interaction was detected (p = 0.001), indicating a significantly different rest-to-peak P(a-ET)CO$_2$ change across the three study groups. Indeed, post hoc contrasts revealed no significant rest-to-peak change of P(a-ET)CO$_2$ in LVAD and HFrEF-matched, whereas a significant decrease was observed in HFrEF$\geq$14. Accordingly, peak P(a-ET)CO$_2$ became more positive the more severe the exercise limitation was (Table 5 and Fig 1).

In LVAD, a multiple regression model including possible clinical/instrumental determinants of alveolar wasted ventilation (r = 0.99, r$^2$ = 0.91, p < 0.0001), selected TAPSE/PASP ratio and blood urea nitrogen/creatinine ratio as independent predictors of peak P(a-ET)CO$_2$ (Table 6).

Table 4. Arterial blood gas analysis parameters.

| LVAD       | HFrEF-matched | HFrEF$\geq$14 | ANOVA |
|------------|---------------|---------------|-------|
| Resting PO$_2$ (mmHg) | 85.8±9.4 | 85.5±10.9 | 85.8±9.1 | 0.97 |
| Peak PO$_2$ (mmHg) | 91.5±15.4 | 93.5±13.3 | 98.3±9.2 | 0.37 |
| Resting SaO$_2$ | 0.98±0.01 | 0.98±0.01 | 0.97±0.01 | 0.55 |
| Peak SaO$_2$ | 0.98±0.02 | 0.98±0.02 | 0.97±0.01 | 0.91 |
| Resting PCO$_2$ (mmHg) | 35.6±4.9 | 35.5±4.3 | 39.8±3.8 * | 0.015 |
| Peak PCO$_2$ (mmHg) | 32.1±4.1 | 33.2±3.6 | 35.9±4.2 * | 0.017 |
| Resting pH | 7.4±0.03 | 7.43±0.03 | 7.40±0.02 | 0.39 |
| Peak pH | 7.41±0.05 | 7.40±0.04 | 7.35±0.05 * | 0.001 |
| Resting HCO$_3^-$ (mmol/l) | 24±2.9 | 24.2±2.2 | 24.8±1.8 | 0.57 |
| Peak HCO$_3^-$ (mmol/l) | 21.1±2.8 | 21.4±2.2 | 20.8±2.3 | 0.35 |

LVAD = left ventricular assist device patients; HFrEF-matched = chronic heart failure patients with peak VO$_2$ matched to that of LVAD; HFrEF$\geq$14 = chronic heart failure patients with peak VO$_2$ $\geq$14 ml/kg/min; ANOVA = analysis of variance; SaO$_2$ = hemoglobin O$_2$ saturation.

* = p <0.01 vs. LVAD and HFrEF-matched.

https://doi.org/10.1371/journal.pone.0187112.t004

Exercise gas exchange in left ventricular assist device

PLOS ONE | https://doi.org/10.1371/journal.pone.0187112 June 1, 2018 7 / 15
Higher than normal and similar resting VD/VT values were found in the 3 groups. A trend towards a larger rest-to-peak decrease of VD/VT was observed in HFrEF than in LVAD and HFrEF-matched, and peak VD/VT was found to be inversely related to peak VO$_2$ (Fig 1) (Table 5).

Rest and peak P(A-a)O$_2$ were normal in all groups (Table 5). However, peak P(A-a)O$_2$ values were related to those of peak VO$_2$ in the study population (Fig 1), and found to be higher in LVAD than in HFrEF ($p<0.01$) (Table 5).

Finally, in LVAD no correlation was observed between P(a-ET)CO$_2$, VD/VT and P(A-a)O$_2$ and time elapsed since implantation ($r$ between 0.18 and 0.35, all $p>0.30$).

**Discussion**

Our results show that, notwithstanding the device support to cardiac function, LVAD-implanted patients still suffer from a severe exercise ventilation/perfusion mismatching, similar to that of patients with stable advanced HFrEF and independent of time elapsed from implantation. Such a pathophysiological picture is characterized by increased alveolar wasted ventilation due to hypoperfusion of normally ventilated alveoli and related to right ventriculo-arterial coupling and effective circulating volume.

**Pathophysiological background**

LVAD implantation determines a peculiar exercise hemodynamic environment, where systemic perfusion can be generated in parallel by the LVAD and the native left ventricle [8,9,18]. Pump-generated blood flow can actually increase during exercise [17,18,29,30], but in any case quite modestly [8,17,18], as expected on the grounds of the reduced preload sensitivity of fixed-pump speed devices [10]. Some contribution of the native left ventricle can also become detectable, but is usually limited as well, ranging between 15 and 25% of peak systemic perfusion [8]. As a consequence, LVAD-implanted patients often suffer from a reduced functional capacity [4–8] due to the limited ability of the LVAD/dysfunctioning left ventricle combination to adapt to the increasing hemodynamic demands of exercise.

**LVAD recipients’ exercise gas exchange**

Resting P(a-ET)CO$_2$ was normal in LVAD and HFrEF-matched and higher than normal in HFrEF$\geq$14. The reason for the latter finding is not straightforward. P(a-ET)CO$_2$ can increase

---

Table 5. Ventilation/perfusion matching parameters.

|                   | LVAD   | HFrEF-matched | HFrEF$\geq$14 | ANOVA   |
|-------------------|--------|---------------|---------------|---------|
| Resting P(a-ET)CO$_2$ (mmHg) | 4.5±2.4 | 4.1±1.4       | 6.5±3.6      | 0.046   |
| Peak P(a-ET)CO$_2$ (mmHg)     | 4.3±2.2 | 3.8±2.5       | 2.8±2.0      | 0.16    |
| Resting VD/VT       | 0.51±0.04 | 0.51±0.04    | 0.49±0.07    | 0.85    |
| Peak VD/VT          | 0.48±0.06 | 0.47±0.07    | 0.44±0.05    | 0.16    |
| Resting P(A-a)O$_2$ (mmHg) | 16.4±9.3 | 13.9±7.4      | 12.4±7.8     | 0.35    |
| Peak P(A-a)O$_2$ (mmHg)     | 25.9±15.0 | 18.6±13.2    | 14.7±6.4     | 0.025   |

LVAD = left ventricular assist device patients; HFrEF-matched = chronic heart failure patients with peak VO$_2$ matched to that of LVAD; HFrEF$\geq$14 = chronic heart failure patients with peak VO$_2$ $\geq$14 ml/kg/min; ANOVA = analysis of variance; P(a-ET)CO$_2$ = arterial-end-tidal PCO$_2$ difference; VD/VT = physiological dead space-tidal volume ratio; P(A-a)O$_2$ = alveolar–arterial PO$_2$ difference.

* = $p<0.01$ vs. LVAD and HFrEF-matched
** = $p<0.01$ vs. HFrEF$\geq$14
# = $p<0.01$ vs. Resting P(a-ET)CO$_2$

Higher than normal and similar resting VD/VT values were found in the 3 groups. A trend towards a larger rest-to-peak decrease of VD/VT was observed in HFrEF$\geq$14 than in LVAD and HFrEF-matched, and peak VD/VT was found to be inversely related to peak VO$_2$ (Fig 1) (Table 5). Rest and peak P(A-a)O$_2$ were normal in all groups (Table 5). However, peak P(A-a)O$_2$ values were related to those of peak VO$_2$ in the study population (Fig 1), and found to be higher in LVAD than in HFrEF$\geq$14 (Table 5).

Finally, in LVAD no correlation was observed between P(a-ET)CO$_2$, VD/VT and P(A-a)O$_2$ and time elapsed since implantation ($r$ between 0.18 and 0.35, all $p>0.30$).

https://doi.org/10.1371/journal.pone.0187112.t005
With age, emphysema, hypovolemia and pulmonary embolism, but no evidence was available for differences as to these points in HFrEF as compared to the other two groups. High ventilation/perfusion ratio with increased wasted ventilation due to low cardiac output state is the obvious alternative cause of increased P(a-ET)CO$_2$, but the higher peak VO$_2$ observed by design in HFrEF$\geq$14 than in LVAD and HFrEF-matched virtually rules out this point as well.

Of note, however, in keeping with previously reported data in HFrEF [15], peak P(a-ET)CO$_2$ was inversely related to peak VO$_2$. Accordingly, a significant rest-to-peak decrease of P(a-ET)CO$_2$ was found in HFrEF$\geq$14, whereas LVAD and HFrEF-matched showed values almost unchanged compared to baseline. The rest-to-peak stability of positive peak P(a-ET)CO$_2$ values observed in LVAD recipients and HFrEF-matched testifies to high alveolar wasted ventilation throughout exercise [31]. These results are conceptually supported by those of Matsuzawa [32], who found a significant direct relationship between PETCO$_2$ at respiratory compensation point and peak cardiac index in HFrEF patients with positive peak P(a-ET)CO$_2$ values. Indeed, the rest-to-peak increase of pump-generated blood flow was modest in LVAD, averaging 1.5 l/min. As highlighted by Robertson [33], such a reduced systemic perfusion can result per se in a ventilation/perfusion ratio increase independently of any underlying degree of regional ventilation/perfusion mismatch. Our data showed an inverse relationship also between peak VO$_2$/VT and peak VO$_2$, but rest-to-peak changes of VO$_2$/VT in the study groups did not reach statistical significance. This might be explained by the fact that changes in alveolar wasted ventilation are somewhat ‘diluted’ in those of total wasted ventilation [19]. Remarkably, multiple regression analysis identified TAPSE/PASP and blood urea nitrogen/creatinine ratio as independent predictors of peak P(a-ET)CO$_2$ in LVAD recipients. TAPSE/PASP ratio has been used as an in vivo descriptor of right ventriculo-arterial coupling [27,28].

### Table 6. Multiple regression testing independent predictors of peak arterial-end-tidal PCO$_2$ difference in left ventricular assist device recipients.

| Coefficient                      | Coefficient |
|----------------------------------|-------------|
| TAPSE/PASP (mm/mmHg)             | -0.60       | 0.042 |
| BUN/Creatinine                   | -0.70       | 0.047 |
| FVC %predicted                   | -0.075      | 0.29  |
| Peak HR (beats/min)              | -0.023      | 0.59  |
| Time since implantation (days)   | 0.001       | 0.73  |
| DL$_{CO}$/VA %predicted          | -0.081      | 0.18  |
| Peak PBF (l/min)                 | -0.11       | 0.22  |
| Peak RR (breaths/min)            | -0.012      | 0.51  |
| LVEF (%)                         | -0.058      | 0.47  |

TAPSE/PASP = tricuspid annular plane systolic excursion-pulmonary artery systolic pressure ratio; BUN = blood urea nitrogen; FVC %predicted = forced vital capacity as percentage of predicted; HR = heart rate; DL$_{CO}$/VA % predicted = hemoglobin-adjusted lung diffusion capacity for carbon monoxide normalized for alveolar volume, expressed as percentage of predicted; PBF = pump blood flow; RR = respiratory rate; LVEF = left ventricular ejection fraction.

https://doi.org/10.1371/journal.pone.0187112.t006
observation of a correlation between TAPSE/PASP ratio and both peak P(a-ET)CO₂ and peak VO₂ in LVAD extends previous data of our laboratory [8], and is consistent with the emerging evidence that right ventricular systolic function is a crucial determinant of functional capacity in several pathophysiological conditions [34–37]. This is even more conceivable in the light of the acknowledged crucial role played by right ventricular systolic function in the management of LVAD recipients both pre- and post-implantation [38]. The blood urea nitrogen/creatinine ratio is commonly used as a descriptor of circulating effective volume status [39]. In this regard, our finding of a blood urea nitrogen/creatinine ratio significantly lower in LVAD recipients than in HFrEF patients seems to describe a higher replenishment of circulation in the former group. It must be acknowledged that blood urea nitrogen/creatinine ratio can increase independently of circulating effective volume in HFrEF patients, due to neurohumoral activation-induced urea reabsorption at the collecting duct level [40]. However, blood urea nitrogen/creatinine ratio was not related with NT pro-BNP in the study population, notwithstanding a strong trend towards higher NT pro-BNP values (i.e. higher neurohumoral activation) in LVAD than in HFrEF patients. This justifies its use as a circulating effective volume descriptor in the present study. As a whole, these data favor the concept of right ventriculo-arterial coupling and repletion of systemic and pulmonary circulation as important factors in allowing for a proper ventilation/perfusion matching after LVAD implantation (Fig 2).

Similarly to previously reported data in HFrEF patients [15], peak P(A-a)O₂ was found to be on average within normal limits in the study population, which should exclude the presence of low ventilation/perfusion ratio mismatching. However, LVAD had peak P(A-a)O₂ values significantly higher than those of HFrEF-matched and HFrEF ≥14. Agostoni [41] has shown that in advanced HFrEF patients alveolar-capillary membrane conductance is reduced shortly after incremental exercise, which could occur more likely in recently implanted patients. In addition, different responses of endothelial cells to laminar vs. oscillatory flow have been described [42,43], and how lack of pulsatile flow may affect alveolar-capillary membrane function in LVAD recipients has not been settled yet.

Of note, the time elapsed since implantation was not related to both ventilation/perfusion matching and peak VO₂, which suggests quite a fixed exercise pathophysiological picture over time in LVAD recipients at least in the short- to medium-term after implantation. In this regard, the scarce adaptability of devices to exercise-induced preload increase is likely to play a preeminent role.

Study limitations

Pump blood flow was estimated by device controllers based on pump speed and power consumption, and must be interpreted with some caution. We studied patients implanted with both axial- (HeartMate II) and centrifugal-flow (HeartWare) LVAD, known to show different sensitivities to changes in head pressure across the pump [9]. As LVAD peak blood pressure was not available in the present study, we cannot exclude that differences in afterload between patients may have influenced pump performance and exercise gas exchange. However, both resting and peak pump blood flow did not differ between patients implanted with HeartMate II and HeartWare devices, which should exclude at least large differences in afterload between the two groups. Ventilation/perfusion mismatch and wasted ventilation were considered the main determinants of the observed gas exchange abnormalities. However, it must be acknowledged that other factors not evaluated in the present study, such as abnormal pulmonary artery pressure increase or arterio-venous shunt during exercise can affect pulmonary gas exchange. In addition, the TAPSE/PASP ratio is a rough estimate of the in vivo right ventriculo-arterial coupling at rest; its role as a determinant of P(a-ET)CO₂ at peak exercise must thus be
interpreted with caution. Given that pulmonary gas exchange has been specifically evaluated in the present study, the concept of 'hypoperfusion' put forward in the manuscript applies only to pulmonary capillaries, thus not allowing inferences about gas exchange in the periphery, i.e. in exercising skeletal muscle [44]. Finally, we evaluated only male patients, so the behaviour of exercise gas exchange in female LVAD recipients remains to be determined.

**Conclusions**

LVAD recipients still suffer from severely reduced functional capacity, similar to those of patients with stable advanced HFrEF. This study demonstrates that such a pathophysiological
picture is mainly characterized by alveolar wasted ventilation and high ventilation/perfusion ratio due to hypoperfusion of normally ventilated alveoli, and is related to right ventriculo-arterial coupling and effective circulating volume. These results provide important insights into exercise pathophysiology of LVAD recipients, useful for the design of control algorithms able to adapt pump blood flow to exercise hemodynamic demands and yield a proper ventilation/perfusion matching.

**Supporting information**

S1 Data file. (XLS)

**Acknowledgments**

The authors are grateful to Elena Bonanomi and Silvia Colombo for their technical support and to Rosemary Allpress for her careful revision of the English manuscript.

**Author Contributions**

**Conceptualization:** Alessandro Mezzani, Massimo Pistono, Piergiuseppe Agostoni, Ugo Corrà.

**Data curation:** Alessandro Mezzani, Andrea Giordano, Marco Gnemmi, Alessandro Imparato, Pierluigi Temporelli.

**Formal analysis:** Alessandro Mezzani, Andrea Giordano.

**Investigation:** Alessandro Mezzani, Marco Gnemmi, Alessandro Imparato, Pierluigi Temporelli, Ugo Corrà.

**Methodology:** Alessandro Mezzani, Alessandro Imparato, Ugo Corrà.

**Supervision:** Alessandro Mezzani, Massimo Pistono, Piergiuseppe Agostoni, Andrea Giordano, Ugo Corrà.

**Writing – original draft:** Alessandro Mezzani.

**References**

1. Daneshmand MA, Rajagopal K, Lima B, Khorrarn N, Blue LJ, Lodge AJ, et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann Thorac Surg. 2010; 89 (4):1205–1209; discussion 1210. https://doi.org/10.1016/j.athoracsur.2009.12.058 PMID: 20338335

2. Holman WL, Naftel DC, Eckert CE, Kormos RL, Goldstein DJ, Kirklin JK. Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011. J. Thorac Cardiovasc Surg. 2013; 146(2):437–441. https://doi.org/10.1016/j.jtcvs.2013.02.018 PMID: 23490245

3. Westaby S. Rotary blood pumps as definitive treatment for severe heart failure. Future Cardiol. 2013; 9 (2):189–213. https://doi.org/10.2217/fca.12.89 PMID: 23463973

4. Abshire M, Dennison Himmelfarb CR, Russell SD. Functional status in left ventricular assist device-supported patients: a literature review. J Card Fail. 2014; 20(12):973–983. https://doi.org/10.1016/j.cardfail.2014.08.011 PMID: 25176994

5. Compostella L, Russo N, Setzi T, Compostella C, Bellotto F. Exercise performance of chronic heart failure patients in the early period of support by an axial-flow left ventricular assist device as destination therapy. Artif Organs. 2014; 38(5):366–373. https://doi.org/10.1111/aor.12172 PMID: 24117945

6. Dunlay SM, Allison TG, Pereira NL. Changes in cardiopulmonary exercise testing parameters following continuous flow left ventricular assist device implantation and heart transplantation. J Card Fail. 2014; 20(8):546–554. https://doi.org/10.1016/j.cardfail.2014.05.008 PMID: 24893345
7. Leibner ES, Cysyk J, Eleuteri K, El-Banayosy A, Boehmer JP, Pae WE. Changes in the functional status measures of heart failure patients with mechanical assist devices. ASAIO J. 2013; 59(2):117–122. https://doi.org/10.1097/MAT.0b013e3182816cb7 PMID: 23438772

8. Mezzani A, Pistono M, Corrà U, Giordano A, Gnemmi M, Imparato A, et al. Systemic perfusion at peak incremental exercise in left ventricular assist device recipients: partitioning pump and native left ventricle relative contribution. Int J Cardiol Heart & Vessels. 2014; 4:40–45.

9. Jung MH, Gustafsson F. Exercise in heart failure patients supported with a left ventricular assist device. J Heart Lung Transplant. 2015; 34(4):489–496. https://doi.org/10.1016/j.healun.2014.11.001 PMID: 25577562

10. Salamonsen RF, Mason DG, Ayre PJ. Response of rotary blood pumps to changes in preload and afterload at a fixed speed setting are unphysiological when compared with the natural heart. Artif Organs. 2011; 35(3):E47–E53. https://doi.org/10.1111/j.1525-1594.2010.01168.x PMID: 21355872

11. Scheiderer R, Belden C, Schwab D, Haney C, Paz J. Exercise guidelines for inpatients following ventricular assist device placement: a systematic review of the literature. Cardiopulm. Phys Ther J. 2013; 24(2):35–42. PMID: 23801903

12. AlOmari AH, Savkin AV, Stevens M, Mason DG, Timms DL, Salamonsen RF, et al. Developments in control systems for rotary left ventricular assist devices for heart failure patients: a review. Physiol Meas. 2013; 34(1):R1–R27. https://doi.org/10.1088/0967-3334/34/1/R1 PMID: 23242235

13. Salamonsen RF, Lim E, Gaddum N, AlOmari AH, Gregory SD, Stevens M, et al. Theoretical foundations of a Starling-like controller for rotary blood pumps. Artif Organs. 2012; 36(9):787–796. https://doi.org/10.1111/j.1525-1594.2012.01457.x PMID: 22626056

14. Petersson J, Glenny RW. Gas exchange and ventilation-perfusion relationships in the lung. Eur Respir J. 2014; 44(4):1023–1041. https://doi.org/10.1183/09031936.00037014 PMID: 25063240

15. Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koke A, Lubarsky L et al. Lung function and exercise gas exchange in chronic heart failure. Circulation. 1997; 96(7):2221–2227. PMID: 9337193

16. Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, Sun X-G, Whipp BJ. Principles of exercise testing and interpretation. Including pathophysiology and clinical applications. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.

17. Akimoto T, Yamazaki K, Litwak P, Litwak KN, Tagusari O, Mori T, et al. Rotary blood pump flow spontaneously increases during exercise under constant pump speed: results of a chronic study. Am J Respir Crit Care Med. 1999; 23(8):797–801. PMID: 10463510

18. Jacquet L, Vancaenenegem O, Pasquet A, Matte P, Poncet A, Price J, et al. Exercise capacity in heart failure patients supported with a left ventricular assist device. J Am Coll Cardiol. 2011; 57(12):1062–1070. https://doi.org/10.1016/j.jacc.2011.05.00034805 PMID: 21615428

19. Robertson HT. Dead space: the physiology of wasted ventilation. Eur Respir J. 2015; 45(6):1704–1716. https://doi.org/10.1183/09031936.0037614 PMID: 25395032

20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al; ATS/ERS Task Force. Standardization of spirometry. Eur Respir J. 2005; 26(2):319–338. https://doi.org/10.1183/09031936.00048005 PMID: 16055882

21. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40(6):1324–1343. https://doi.org/10.1183/09031936.00080312 PMID: 22743675

22. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique—1995 update. Am. J. Respir Crit Care Med. 1995; 152(6 Pt 1):2185–2198.

23. Marrades RM, Diaz O, Roca J, Campistol JM, Torregrosa JV, Barberà JA, et al. Adjustment of DLCO for hemoglobin concentration. Am J Respir Crit Care Med. 1997; 155(1):236–241. https://doi.org/10.1164/ajccr.1997.155.1.9001318 PMID: 9001318

24. Aguilaniu B, Maître J, Génet S, Gégout-Petit A, Guénard H. European reference equations for CO and NO lung transfer. Eur Respir J. 2008; 31(5):1091–1097. https://doi.org/10.1183/09031936.00063207 PMID: 18216061

25. Johnson DC. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume. Respir Med. 2000; 94(1):28–37. https://doi.org/10.1016/S0954-1320(99)00074-X PMID: 10714476

26. Ammar KA, Umland MM, Kramer C, Sulemanjee N, Jan MF, Khandheria BK, et al. The ABCs of left ventricular assist device echocardiography: a systematic approach. Eur J Heart Cardiovasc Imaging. 2012; 13(11):885–899. https://doi.org/10.1093/ehjci/jes090 PMID: 22581283
27. Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol. 2013; 305(9):H1373–H1381. https://doi.org/10.1152/ajpheart.00157.2013 PMID: 23997100

28. Guazzi M, Naeije R, Arena R, Corrà U, Ghio S, Forfia P, et al. Echocardiography of right ventriculoarterial coupling combined with cardiopulmonary exercise testing to predict outcome in heart failure. Chest. 2015; 148(1):226–234. https://doi.org/10.1378/chest.14-2065 PMID: 25633590

29. Hu SX, Keogh AM, Macdonald PS, Kotlyar E, Robson D, Harkess M, et al. Interaction between physical activity and continuous-flow left ventricular assist device function in patients. J Card Fail. 2013; 19(3):169–175. https://doi.org/10.1016/j.cardfail.2013.01.008 PMID: 23997100

30. Martina J, de Jonge N, Rutten M, Kirkels JH, Klopping C, Rodermans B, et al. Exercise hemodynamics during extended continuous flow left ventricular assist device support: the response of systemic cardiovascular parameters and pump performance. Artif Organs. 2013; 37(9):754–762. https://doi.org/10.1111/aor.12151 PMID: 24074245

31. Whipp BJ, Wasserman K. Alveolar-arterial gas tension differences during graded exercise. J Appl Physiol. 1969; 27(3):361–365. https://doi.org/10.1152/jappl.1969.27.3.361 PMID: 5804133

32. Matsumoto A, Itoh H, Eto Y, Kobayashi T, Kato M, Omata M, et al. End-tidal CO₂ pressure decreases during exercise in cardiac patients: association with severity of heart failure and cardiac output reserve. J Am Coll Cardiol. 2000; 36(1):242–249. PMID: 10898441

33. Robertson HT. Gas exchange consequences of left heart failure. Compr Physiol. 2011; 1(2):621–634. https://doi.org/10.1002/cphy.c100010 PMID: 23737197

34. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995; 25(5):1143–1153. PMID: 7897128

35. Blumberg FC, Arzt M, Lange T, Schroll S, Pfeifer M, Wensel R. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. Eur J Heart Fail. 2013; 15(7):771–777. https://doi.org/10.1002/ejhf.htf044 PMID: 23507788

36. Friedberg MK, Fernandes FP, Roche SL, Storach C, Grosse-Wortmann L, Manhiot C, et al. Relation of right ventricular mechanics to exercise tolerance in children after tetralogy of Fallot repair. Am Heart J. 2013; 165(4):551–557. https://doi.org/10.1016/j.ahj.2012.06.029 PMID: 23379792

37. Morrison DA, Adcock K, Collins CM, Goldman S, Caldwell JH, Schwarz MI. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol. 1987; 9(6):1219–1229. PMID: 3584714

38. Cameli M, Sparla S, Focardi M, Righini FM, Solari M, Alvino F, et al. Evaluation of right ventricular function in the management of patients referred for left ventricular assist device therapy. Transplant Proc. 2015; 47(7):2166–8. https://doi.org/10.1016/j.transproceed.2015.02.032 PMID: 26361669

39. Rose BD. Clinical physiology of acid-base and electrolyte disorders. 5th edition. New York, NY: McGraw-Hill, Inc.; 2000.

40. Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail. 2008 May; 1(1):2–5. https://doi.org/10.1161/CIRCHEARTFAILURE.108.770834 PMID: 19808263

41. Agostoni P, Cattadori G, Bianchi M, Wasserman K. Exercise-induced pulmonary edema in heart failure. Circulation. 2003; 108(21):2666–2671. https://doi.org/10.1161/01.CIR.0000097115.61309.59 PMID: 14581402

42. Li YS, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech. 2005; 38(10):1949–1971. https://doi.org/10.1016/j.jbiomech.2004.09.030 PMID: 16084198

43. Soucy KG, Koenig SC, Giridharan GA, Sobieski MS, Slaughter MS. Rotary pumps and diminished pulsatility: do we need a pulse? ASAIO J. 2013; 59(4):355–366. https://doi.org/10.1097/MAT.0b013e31829f9bb3 PMID: 23820272

44. Loyaga-Rendon RY, Pleasance EP, Arena R, Shah K. Exercise physiology, testing, and training in patients supported by a left ventricular assist device. J Heart Lung Transplant. 2015; 34(8):1005–1016. https://doi.org/10.1016/j.healun.2014.12.006 PMID: 25682553